Clinical Trials Browser

Hematologic Neoplasms

NCT04164199 2026-03-16

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Phase 3 Enrolling by invitation

430 enrolled

Advanced Malignancies

NCT05523323 2026-03-13

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension

Phase 3 Completed

112 enrolled 16 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02811861 2026-02-23

CLEAR

Phase 3 Active not recruiting

1,069 enrolled 12 charts 1 FDA

Genitourinary

Carcinoma, Renal Cell

NCT03829332 2026-02-19

LEAP-007

Phase 3 Completed

623 enrolled 26 charts

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT04039607 2026-02-19

CheckMate 9DW

Phase 3 Active not recruiting

732 enrolled 1 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT07405164 2026-02-12

MK-6482-043

Phase 3 Not yet recruiting

450 enrolled

Genitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT03820986 2026-02-09

LEAP-003

Phase 3 Completed

674 enrolled 21 charts

Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT03713593 2026-02-05

LEAP-002

Phase 3 Completed

794 enrolled 30 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Hepatocellular

NCT03829319 2026-02-05

LEAP-006

Phase 3 Completed

761 enrolled 31 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT03898180 2026-02-05

LEAP-011

Phase 3 Completed

505 enrolled 19 charts

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

NCT04776148 2026-02-05

MK-7902-017

Phase 3 Completed

563 enrolled 32 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT03884101 2026-02-02

LEAP-001

Phase 3 Completed

842 enrolled 25 charts

Gynecologic

Endometrial Neoplasms

NCT04889118 2025-12-23

LEAP-003

Phase 3 Completed

131 enrolled 16 charts

Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

Clinical Trials

MK-3475-587

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension

CLEAR

LEAP-007

CheckMate 9DW

MK-6482-043

LEAP-003

LEAP-002

LEAP-006

LEAP-011

MK-7902-017

LEAP-001

LEAP-003